Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03775460
NA

Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum

Sponsor: London School of Hygiene and Tropical Medicine

View on ClinicalTrials.gov

Summary

Erythema Nodosum Leprosum (ENL) is a painful, debilitating complication of leprosy. Patients often require high doses of corticosteroids for prolonged periods. Thalidomide is expensive and not available in most countries. The use of corticosteroids for long periods is associated with adverse effects and mortality. It is a priority to identify alternative agents to treat ENL. Methotrexate (MTX) is a cheap, widely used medication which has been reported to be effective in ENL resistant to steroids and thalidomide.

Official title: Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

550

Start Date

2023-01-15

Completion Date

2025-10-01

Last Updated

2025-09-10

Healthy Volunteers

No

Interventions

DRUG

Methotrexate

Participants in the intervention group will receive methotrexate along side prednisolone

DRUG

Placebo

Participants in the control arm will receive placebo along side prednisolone

DRUG

Prednisolone

Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks

Locations (7)

TMLI Bangladesh/ DBLM hospital

Dhaka, Bangladesh

FIOCRUZ

Rio de Janeiro, Brazil

ALERT

Addis Ababa, Ethiopia

The Leprosy Mission Trust

Delhi, India

Bombay Leprosy Project

Mumbai, India

Soetomo Hospital

Surabaya, Indonesia

Anandaban Hospital

Kathmandu, Nepal